B5437

Bendamustine hydrochloride hydrate

≥98% (HPLC)

• Synonim(y): 1H-Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl monohydrochloride, Treanda
• Wzór empiryczny (zapis Hilla): C₁₆H₂₁Cl₂N₃O₂·HCl · xH₂O
• Numer CAS: 1374784-02-7
• Masa cząsteczkowa: 394.72 (anhydrous basis)
• NACRES: NA.77
• PubChem Substance ID: 329773260
• UNSPSC Code: 12352200
• MDL number: MFCD16879055
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: off-white
• solubility: H₂O: >30 mg/mL
• originator: Teva
• storage temp.: room temp
• SMILES string: O.Cl.Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl
• InChI: 1S/C16H21Cl2N3O2.ClH.H2O/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H;1H2
• InChI key: TWBJYCLUHINEDN-UHFFFAOYSA-N

Opis

General description

Bendamustine comprises 2-chloroethylamine alkylating group, a butyric acid side chain and a benzimidazole ring in its structure[1] and is a nitrogen mustard.[1] It is catabolized in the liver by the enzyme cytochrome P450 1A2 into γ hydroxyl-bendamustine and N-desmethyl-bendamustine.

Application

Bendamustine hydrochloride hydrate has been used as:

• a chemotherapy agent for chronic lymphocytic leukemia (CLL) samples to monitor spliced and unspliced gene expression[2]
• an inhibitor to E3 ubiquitin-protein ligase RNF3 (HOIP) in matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF) assay[3]
• a cytotoxic chemotherapeutic drug in high-throughput screening to test interaction with BAY87-2243[4]

Biochem/physiol Actions

Bendamustine hydrochloride is a DNA-alkylator with a distinct pattern of activity. Bendamustine activates DNA-damage stress response and apoptosis; inhibits mitotic checkpoints; and induces mitotic catastrophe.

Bendamustine is a therapeutic agent employed in treating lymphomas and chronic lymphocytic leukemia.[3] It may be useful in central nervous system (CNS) malignancies treatment regimen due to its penetration capacity into brain tissue.[5] Bendamustine is a promising candidate for non-Hodgkin lymphoma and Hodgkin lymphoma therapies.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Teva. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS06,GHS08
• signalword: Danger
• hcodes: H301,H341,H351,H361fd
• pcodes: P202 - P264 - P270 - P280 - P301 + P310 - P405
• Hazard Classifications: Acute Tox. 3 Oral - Carc. 2 - Muta. 2 - Repr. 2
• Klasa składowania: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Faceshields, Gloves